5:01 PM ET
10-Q
Financial Results
Elutia Q3 2026 Results: Net Loss of $1.28M, Loss Narrows
Elutia Inc. is focusing on the development of its next-generation biologic scaffolds, NXT-41 and NXT-41x, following the divestiture of its SimpliDerm and Orthobiologics businesses. The company is managing ongoing litigation related to its FiberCel and VBM product recalls while navigating capital requirements and Nasdaq compliance.
- Key figure
- Net loss $1.28M